Özkaya Abdullah, Karabaş Levent, Alagöz Cengiz, Alkın Zeynep, Artunay Özgür, Bölükbaşı Selim, Demir Gökhan, Demir Mehmet, Demircan Ali, Erden Burak, Erdoğan Gürkan, Erdoğan Mehmet, Eriş Erdem, Kaldırım Havva, Onur İsmail Umut, Osmanbaşoğlu Özen, Özdoğan Erkul Sezin, Öztürk Mine, Perente İrfan, Sarıcı Kübra, Sayın Nihat, Yaşa Dilek, Yılmaz İhsan, Yılmazabdurrahmanoğlu Zeynep
Bosphorus Retina Study Group.
Beyoğlu Eye Training and Research Hospital, Ophthalmology Clinic, İstanbul, Turkey.
Turk J Ophthalmol. 2018 Oct;48(5):232-237. doi: 10.4274/tjo.31697. Epub 2018 Oct 31.
To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients.
Multicenter, retrospective, interventional, non-comparative study. The records of nAMD patients treated with an anti-VEGF agent on a pro re nata treatment regimen basis between January 2013 and December 2015 were reviewed. The patients who completed a follow-up period of 12 months were included. Primary outcome measures of this study were the visit and injection numbers during the first year.
Eight hundred eighty eyes of 783 patients met the inclusion criteria for the study. Mean number of visits at month 12 was 6.9±2.5 (range: 1-15). Mean number of injections at month 12 was 4.1±1.9 (range: 1-11). Mean visual acuity at baseline and months 3, 6, and 12 was 0.90±0.63 LogMAR (range: 0.0-3.0), 0.79±0.57 LogMAR (range: 0.0-3.0), 0.76±0.57 LogMAR (range: 0.0-3.0), and 0.79±0.59 LogMAR (range: 0.0-3.0), respectively. Mean central retinal thickness at baseline and months 6 and 12 was 395±153 μm (range: 91-1582), 330±115 μm (range: 99-975), and 332±114 μm (range: 106-1191), respectively.
The numbers of visits and injections were much lower than ideal and were insufficient with the pro re nata treatment regimen.
评估玻璃体内注射抗血管内皮生长因子（anti-VEGF）治疗新生血管性年龄相关性黄斑变性（nAMD）患者的真实世界疗效。
多中心、回顾性、干预性、非对照研究。回顾了2013年1月至2015年12月期间根据按需治疗方案接受抗VEGF药物治疗的nAMD患者的记录。纳入完成12个月随访期的患者。本研究的主要结局指标是第一年的就诊次数和注射次数。
783例患者的880只眼符合研究纳入标准。12个月时的平均就诊次数为6.9±2.5（范围：1 - 15）。12个月时的平均注射次数为4.1±1.9（范围：1 - 11）。基线时以及第3、6和12个月时的平均视力分别为0.90±0.63 LogMAR（范围：0.0 - 3.0）、0.79±0.57 LogMAR（范围：0.0 - 3.0）、0.76±0.57 LogMAR（范围：0.0 - 3.0）和0.79±0.59 LogMAR（范围：0.0 - 3.0）。基线时以及第6和12个月时的平均中心视网膜厚度分别为395±153μm（范围：91 - 1582）、330±115μm（范围：99 - 975）和332±114μm（范围：106 - 1191）。
就诊次数和注射次数远低于理想水平，按需治疗方案并不充分。
